The eIF4E inhibitor ribavirin as a potential antilymphoma therapeutic: early clinical data<sup/>

Leuk Lymphoma. 2018 Jan;59(1):256-258. doi: 10.1080/10428194.2017.1323270. Epub 2017 Jun 2.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antiviral Agents / therapeutic use
  • Eukaryotic Initiation Factor-4E / antagonists & inhibitors*
  • Eukaryotic Initiation Factor-4E / metabolism
  • Humans
  • Lymphoma / drug therapy*
  • Lymphoma / metabolism
  • Lymphoma / virology
  • Remission Induction
  • Respiratory Syncytial Virus Infections / drug therapy
  • Respiratory Syncytial Virus Infections / metabolism
  • Respiratory Syncytial Virus Infections / virology
  • Respiratory Syncytial Viruses / drug effects
  • Retrospective Studies
  • Ribavirin / therapeutic use*

Substances

  • Antiviral Agents
  • Eukaryotic Initiation Factor-4E
  • Ribavirin